PG15 COMPARING THE COST-EFFECTIVENESS OF THE INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV): A MODEL EVALUATING THE CLINICAL AND ECONOMIC IMPACT OF CURRENT TREATMENT OPTIONS  by Goldberg, LD
A44 Abstracts
CLUSIONS: Loss of HBeAg is responsive to dose and duration
in the treatment with interferon-a. A high-dose (≥5MU) and
regular-duration (16–24 weeks) interferon-a is effective than in
clearing virological and serological markers. A dose ≥5MU and
a duration 16–24 week interferon-a is recommended to use.
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OBJECTIVES: The gastrointestinal (GI) risks associated with
selective cyclooxygenase-2 inhibitors (COX-2s) versus non-
selective non-steroidal anti-inﬂammatory drugs (NSAIDs)
among arthritis patients are well documented in clinical trials.
This study is to estimate the major GI risks among elderly
chronic users of COX-2s versus NSAIDs, with/without aspirin
(ASA), in clinical practice. METHODS: A cohort study was con-
ducted using secondary data from the GE logician database
(Centricity EMR), which contained medical records of 3 million
patients seen by 5,000 physicians across 27 states. Inclusion cri-
teria: chronic use (2 or more medication mentions) of COX-2s
or NSAIDs within 60 days between 1/1/1999 and 6/30/2003, 65
or older, no switch between COX-2s and NSAIDs during one-
year follow-up or before a major GI event, deﬁned as GI hem-
orrhage including melena (ICD-9 codes: 578.xx). Descriptive
and multivariate logistic analyses were conducted to determine
how major GI risks differed across chronic users of COX-2s
alone, NSAIDs alone, COX-2s + ASA, and NSAIDs + ASA. The
logistic analysis controlled for gender, age, pre- or post-index GI-
harmful drug use, major and minor GI events in the year prior
to index date, and prior GI-protective drug use. RESULTS: The
number of patients and the percent having major GI events
during one-year follow-up period were as follows: COX-2s-
alone 7,338 (1.73%); NSAIDs-alone 3,826 (2.06%); COX-2s +
ASA 963 (1.77%); and NSAIDs + ASA 602 (2.66%). The mul-
tivariate logistic results showed that compared to COX-2s-alone
users, NSAIDs-alone and NSAIDs + ASA users had higher major
GI risks (OR = 1.35, p = 0.04, 95% CI: 1.01–1.80; and OR =
1.68, p = 0.06, 95% CI: 0.99–2.86 respectively). COX-2s + ASA
users had similar risks (OR = 0.96, p = 0.88, 95% CI: 0.57–1.61)
to COX-2s-alone users. CONCLUSIONS: The major GI risk
was highest among elderly chronic users of NSAIDs + ASA, fol-
lowed by NSAIDs-alone. Only NSAIDs-alone users had a statis-
tically signiﬁcant higher risk than COX-2s-alone users. The
addition of ASA did not signiﬁcantly increase major GI risk
among COX-2 users.
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OBJECTIVES: Few trials directly compared lamivudine with
adefovir in patients with HBeAg-positive and HBeAg-negative
chronic hepatitis B (CHB). This study used direct and indirect
comparison methods to compare the relative efﬁcacy of lamivu-
dine to adefovir. METHODS: We searched Medline, SCI-
expanded, Current Content Connect, Cochrane Library and
Chinese Biomedical Database to September 15, 2005, and man-
ually screened the references of included studies. Trials for
HBeAg-positive and HBeAg-negative CHB were included if they
directly compared lamivudine with adefovir, or compared
lamivudine (or adefovir) with placebo/non-treatment. Direct
comparison was made by pooling the trials of lamivudine versus
adefovir. An adjusted indirect comparison was performed by 
calculating the difference of pooled estimates of lamivudine and
adefovir, which was obtained from trials of lamivudine (or 
adefovir) versus placebo/no treatment. RESULTS: Eight trials 
(n = 1324) were included. Of these, six were trials for HBeAg-
positive CHB patients, and two for HBeAg-negative CHB
patients. One trial compared lamivudine with adefovir in lamivu-
dine-resistant patients with HBeAg-positive CHB, and seven
trials compared lamivudine (or adefovir) with placebo/non-treat-
ment in naïve patients. Quality was medium-to-high in most
trials. The direct comparison for lamivudine-resistant patients
showed that lamivudine with adefovir were equivalent in clear-
ing serological markers, lamivudine was less effective in nor-
malizing ALT (OR = 0.11, 95%CI = 0.013–0.97) but superior
in histological response (OR = 2.08, 95%CI = 1.08–4.04). Indi-
rect comparison from four trials (n = 915) showed that lamivu-
dine and adefovir were equally effective in serological and
biomedical markers in naïve patients with HBeAg-positive CHB.
Indirect comparison from two trials (n = 282) showed that
lamivudine was more effective in normalization of ALT than 
adefovir in HBeAg-negative CHB. But no data on serological and
histological response were available. CONCLUSION: Lamivu-
dine and adefovir was equally effective for naïve patients with
HBeAg-positive CHB. Larger direct comparison trials for




COMPARING THE COST-EFFECTIVENESS OF THE
INTERFERONS (IFNS) UTILIZED IN THE TREATMENT OF
CHRONIC HEPATITIS C VIRUS (HCV): A MODEL EVALUATING
THE CLINICAL AND ECONOMIC IMPACT OF CURRENT
TREATMENT OPTIONS
Goldberg LD
Goldberg, MD & Associates, Battle Ground, WA, USA
OBJECTIVES: The interferons (IFNs) currently indicated for the
treatment of chronic Hepatitis C Virus (HCV) have been shown
to exhibit varying responsiveness in terms of achieving a sus-
tained viral response (SVR). It is the objective of this model to
be used as tool to compare the relative cost-effectiveness of these
agents from a payer perspective. METHODS: An interactive
Excel-based model was developed to compare the relative cost
of treating chronic HCV in terms of both treatment naïve and
pegylated-IFN nonresponders. Drug effectiveness with respect to
the SVR rate was based on the published literature for therapy
in combination with weight-based ribavirin. Drug costs were
based on average wholesale price cost with consideration of con-
tractual discounts and patient co-payment. The primary eco-
nomic endpoint was the drug cost per SVR obtained. Results
were displayed for treatment naïve, pegylated-IFN nonrespon-
ders, and combined cases respectively. Multi-factor sensitivity
analyses were conducted. RESULTS: In a typical managed care
population, with an estimated prevalence of chronic HCV of
1.4% and with 5% of patients being treated, the drug cost of
HCV treatment is $1.22 PMPM. For treatment naïve patients,
Genotype I, the cost per SVR obtained is $31,356, $51,152, and
$19,113 for Pegasys, Peg-Intron, and consensus interferon
(CIFN) respectively. For treatment naïve patients, Genotypes 2/3,
the cost per SVR obtained is $18,030, $24,890, and $12,305 for
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Pegasys, Peg-Intron, and CIFN respectively. For pegylated-IFN
nonresponders, the cost per SVR obtained is $287,516,
$325,515, and $68,880 for Pegasys, Peg-Intron, and CIFN
respectively. CONCLUSION: Treatment of chronic HCV infec-
tion with CIFN is the most cost-effective approach in terms of
minimizing both drug costs and the cost per SVR obtained. This
economic modeling tool helps demonstrate the value of using evi-
dence-based data to link costs to outcomes and how the avail-
able IFNs vary signiﬁcantly in their cost per SVR obtained.
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OBJECTIVES: It is estimated that up to 1.4 million prison
inmates are infected with hepatitis C each year. The study objec-
tive is to assess the cost-effectiveness of screening in the incar-
cerated population of Maryland’s correctional facilities, from a
societal perspective. METHODS: We used a Markov model with
a 1-year cycle length, to simulate hepatitis C disease progression
in a hypothetical cohort of prisoners, mean age 30 years old, and
largely (90%) males, whose estimated incarceration time is at
least 15 months. The screening strategy included a preliminary
test by ELISA followed by conﬁrmatory qualitative PCR. The
treatment consisted of combination therapy (pegylated inter-
feron and ribavirin) for 48 and 24 weeks in patients with geno-
type 1 and genotype 2 or 3 respectively. Costs (2004, US dollars)
and effectiveness measures (Quality Adjusted Life Years—
QALYs) were discounted at 3%. Costs, speciﬁcity, and sensitiv-
ity of tests were obtained from published studies. Age and gender
speciﬁc mortality rates were obtained from U.S. life tables. Esti-
mates of disease progression rates were obtained from previously
published cost-effectiveness studies of combination treatment.
Treatment efﬁcacy rates were obtained from pooled studies of
randomized controlled clinical trials. Detailed resources utiliza-
tion costs in each of the clinical states (hospitalizations, medica-
tions, interventions, and outpatient visits) were obtained from a
previously published study. QALYs for each clinical state were
obtained from a previously published estmiations using a panel
of hepatologists. Univariate sensitivity analyses were performed
to control for uncertainty. RESULTS: The incremental cost effec-
tiveness of screening relative to no screening was $952 per QALY
gained. The model was robust to the changes in the plausible
values of the parameters. CONCLUSIONS: Our model indicates
that it is cost-effective to screen prison populations.
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OBJECTIVES: The economic evaluation of Tegaserod was per-
formed using data from a randomised, double-blind, placebo-
controlled, parallel group, multinational, multi-centre study to
assess the efﬁcacy of treatment with Tegaserod 6mg bid and
Placebo in women with IBS-C. The study consisted of a screen-
ing period, a 2-week baseline period without medication, and a
4-week placebo-controlled treatment period. METHODS: A
total of 2660 patients were randomized, to receive either
Tegaserod (n = 2135) or Placebo (n = 525). Patients’ utility were
obtained using the EQ-5D at baseline, 2 and 4 weeks, and used
to construct a quality-adjusted life year (QALY) for each patient.
The EQ-5D was completed by a subpopulation of 277 patients
(235 Tegaserod: 42 Placebo). The economic perspective was that
of a third party pharmacy payer, based only on the cost of
Tegaserod. Other costs were not included. It was assumed that
patients receiving Placebo represent untreated patients and the
cost of drugs in this arm was set at zero. The gain in QALYs for
each patient was calculated as the area under the utility curve
from baseline to four week follow-up. RESULTS: The utility data
suggests that patients in the Tegaserod group have a signiﬁcantly
higher, 0.074 (95% CI: 0.009 to 0.139; p = 0.027), EQ-5D score
at follow-up than Placebo treated patients after adjusting for
baseline utility score. CONCLUSIONS: These utilities convert to
an estimated QALY of 0.052 for Tegaserod patients vs. 0.048
for Placebo: difference 0.004 QALYs. At an assumed drug cost
of $5.00 per day, the estimated difference in costs, over the 4-
week treatment period between the Tegaserod and Placebo
treated patients is $140, which leads to an ICER of
$33,004/QALY which is under the recommended threshold of
$50,000/QALY for the C-E of new treatments.
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OBJECTIVE: To use a decision model to determine the condi-
tions under which using a clinical decision aid (CDA) for esti-
mating the presence of large esophageal varices (LEVs) in
patients with cirrhosis would be cost-effective compared with the
current standard of screening all patients (ALL). METHODS:
Based on previous Markov decision model results we incorpo-
rated hemodynamic monitoring to assess response following
beta-blocker therapy in both strategies. Variceal bleeding is
treated with ligation and with transjugular intrahepatic portal-
systemic shunt (TIPS) for refractory bleeding. Probabilities of
treatment responses, risks of bleeding and mortality, and test
characteristics of the CDA were based on published literature.
Only direct costs discounted at 3% were considered during the
5-year time horizon. Outcomes included costs, life-years,
QALYs, and percentages of patients bleeding, receiving TIPS,
and dying from any cause. Sensitivity analysis was performed on
CDA sensitivity, speciﬁcity, and LEV prevalence (base 75%,
70%, and 24% respectively). RESULTS: The ALL strategy cost
$406 more than the CDA strategy, but resulted in the most 
life-years, and had an incremental cost-effectiveness ratio of
$34,637/LY compared with the CDA strategy. The CDA strat-
egy was more cost-effective for certain values of sensitivity, speci-
ﬁcity, and prevalence. With a willingness to pay of $50K/LY and
70% speciﬁcity, the ALL strategy was not cost-effective when the
CDA sensitivity was >81%, or when LEV prevalence was <18%.
For 90% speciﬁcity, corresponding thresholds were >76% sensi-
tivity and <24% prevalence. For 55% speciﬁcity, thresholds were
>87% and <13%, respectively. Use of QALYs increased thresh-
olds for sensitivity and reduced those for prevalence of LEV for
all speciﬁcity values. CONCLUSION: The model indicates that
although screening all cirrhotic patients for LEV is cost-effective
compared with the base-case CDA strategy, a CDA strategy may
be preferred under conditions of lower LEV prevalence or better
CDA sensitivity.
